stockrowCRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024.
- Revenue
- +1,325.1%
- EPS
- +1.55%
- Free cash flow
- −6.36%
Quarter to September 2026, against a year earlier
Follow CRSP
Alert me
CRISPR Therapeutics AG (CRSP) P/S ratio
As of 6 November 2026, CRISPR Therapeutics AG (CRSP) trades at a P/S ratio of 192×. Over the past ten years it has ranged from 0.0× (December 2016) to 19,266× (January 2021); the current reading is higher than 72% of that period. That is above the Biotechnology industry median of 9.4× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 1,343× | 1,409.81% |
| FY2024 | 89.0× | 531.19% |
| FY2023 | 14.1× | (99.47%) |
| FY2022 | 2,661× | 42,199.90% |
| FY2021 | 6.3× | (99.96%) |
| FY2020 | 14,044× | 122,657.56% |
| FY2019 | 11.4× | (97.39%) |
| FY2018 | 439× | 1,683.63% |
| FY2017 | 24.6× | (53.95%) |
| FY2016 | 53.4× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 213× | (45.91%) |
| Jun 2026 | 393× | (64.70%) |
| Mar 2026 | 1,114× | (17.11%) |
| Dec 2025 | 1,343× | 770.39% |
| 38 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MANE Veradermics Incorporated compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | 3.4× |
| TVTX Travere Therapeutics, Inc. compare | 7.2× |
| CRSP CRISPR Therapeutics AG | 192× |
| COGT Cogent Biosciences, Inc. compare | 233× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,823× |
| Biotechnology industry median | 9.4× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on CRSP
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement